Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial

Launched by THE GEORGE INSTITUTE · Apr 2, 2024

Keywords

ClinConnect Summary

The ACT-GLOBAL trial, specifically the ENCHANTED3/MT study, is looking at how to best manage high blood pressure in patients who have had an ischemic stroke and received a specific treatment called endovascular therapy (EVT). The goal is to find out which approach to lowering blood pressure works best for these patients. Researchers will include around 2,000 participants with high blood pressure readings of 150 mmHg or more after their EVT. They will be divided into three groups: one group will have no or minimal blood pressure reduction, another will have a moderate reduction, and the third will have a more intensive reduction in blood pressure.

To be eligible for this trial, participants must be at least 18 years old, have undergone EVT within 24 hours of their stroke symptoms, and have sustained high blood pressure shortly after the procedure. It's important to note that individuals with certain medical conditions that prevent them from safely lowering their blood pressure will not be included in the study. Participants can expect to receive careful monitoring and treatment tailored to their assigned blood pressure management strategy throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years;
• • 2. Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines;
• • 3. Sustained high systolic blood pressure ≥150 mmHg (2 readings \<10 mins apart) within 3 hours after completion of EVT.
• Exclusion Criteria:
• • 1.Any definite contraindications to BP lowering treatment.